Dopamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database by Beaulieu, Jean-Martin et al.
IUPHAR/BPS Guide to Pharmacology CITE
https://doi.org/10.2218/gtopdb/F20/2019.4
Dopamine receptors (version 2019.4) in the IUPHAR/BPS Guide to
Pharmacology Database
Jean-Martin Beaulieu1, Emiliana Borrelli2, Arvid Carlsson3, Marc G. Caron4, Olivier Civelli5, Stefano Espinoza6,
Gilberto Fisone7, Raul R. Gainetdinov8, David K. Grandy9, John W. Kebabian10, Saloman Z. Langer11, Maria
Cristina Missale12, Kim A. Neve9, Bernard Scatton13, Jean-Charles Schwartz14, Goran Sedvall7, Philip
Seeman1, David R. Sibley15, Pierre Sokoloff14, Pierre F. Spano16 and Hubert H. M. Van Tol1
1. University of Toronto, Canada
2. University of California Irvine, USA
3. University of Göteborg, Sweden
4. Duke University, USA
5. University of California at Irvine, USA
6. Istituto Italiano di Tecnologia, Italy
7. Karolinska Institutet, Sweden
8. St. Petersburg State University, Russia
9. Oregon Health & Science University, USA
10. Research Biochemical Incorporated, USA
11. Compugen, Israel
12. University of Brescia, Italy
13. Sanofi Synthelabo Recherche, France
14. INSERM, France
15. National Institutes of Health, USA
16. Universitâ degli Studi di Brescia, Italy
Abstract
Dopamine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Dopamine Receptors
[363]) are commonly divided into D1-like (D1 and D5) and D2-like (D2, D3 and D4) families, where the
endogenous agonist is dopamine.
Contents
This is a citation summary for Dopamine receptors in the Guide to Pharmacology database (GtoPdb). It exists
purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation
analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here
under database links.
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
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parts.
Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
in which the family or its subfamilies and targets were substantially changed. The links below are to the current
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